Clinical Trial

The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

Study acronym: HO151DLBCL
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The prognosis of Diffuse Large B cell Lymphoma (DLBCL) patients with an early relapse is dismal. Atezolizumab has shown promising activity in relapsed DLBCL patients. Toxicity data on atezolizumab are available for \> 6000 patients and is manageable. The assumption of this study is that atezolizumab consolidation will result in higher disease free survival by eradicating minimal residual disease In melanoma and lung cancer consolidation immunotherapy after chemoradiotherapy has shown an increase in survival.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2018-03-06; most recent amendment 2026-01-02.
Status change: Recruiting → Active, Not Recruiting 2022-01-19
Status change: Not Yet Recruiting → Recruiting 2018-09-14
Trial Details
NCT Number NCT03463057
Lead Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland
Conditions NHL, DLBCL
Enrollment 109 participants
Start Date 2018-08-30
Primary Completion 2024-01-18 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-05